Competition Pharma Pharmaceutical 
Fierce Pharma
DECEMBER 1, 2023
Turkish authorities have launched an investigation into 19 pharmaceutical companies to probe whether their operations violated the country’s competition law, the Turkish Competition Authority discl | The companies, which include Pfizer, J&J, Sanofi, AbbVie, AstraZeneca, Merck and others are being probed for potentially violating Turkish competition (..)
World of DTC Marketing
OCTOBER 5, 2021
drug pricing system is filled with confusing numbers , and many entities profit off the flow of drugs, but pharmaceutical companies retain a vast majority of the proceeds” Big pharma IS big business. Big Pharma’s chokehold around the U.S. Via Axios “The 10 highest-selling drugs in the U.S. So what’s your point?
World of DTC Marketing
JANUARY 31, 2021
SUMMARY: “How big pharma takeovers destroy innovation” a report from Congresswoman Porter does make some points. I always have pointed instances in which pharma puts Wall Street first and patients second. I have worked with and stayed in contact with some R&D people within pharma and they have a different answer.
MedCity News
NOVEMBER 25, 2024
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.
Healthcare Success
JUNE 6, 2022
What’s more, your highest revenue service lines are likely already facing stiff competition from all angles. . For these reasons and more, it’s imperative to identify your unique selling propositions, review them, and revise them regularly to remain competitive. . So, how can your brand stay competitive? The answer is twofold.
Fierce Pharma
JUNE 23, 2023
After years of using the patent system to delay competition from a rival company and then exhausting that ploy early this year, Jazz Pharmaceuticals is taking a new route—suing the FDA.
European Pharmaceutical Review
NOVEMBER 25, 2022
The Luye Pharma drug demonstrated comparable bioavailability with Johnson and Johnson’s Invega Sustenna ® at steady state in a clinical trial ( NCT04922593 ). The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review.
Expert insights. Personalized for you.
234 
Let's personalize your content